Mylan N.V. (NASDAQ:MYL) Stock Clearly Lies in an Oversold Territory; Shareholders are Watching
Shares of Mylan N.V. (NASDAQ:MYL) tumbled -0.6600% in morning trade Tuesday. The move comes after a leading global pharmaceutical company, has received marketing authorization from the Drug Controller General of India (DCGI) for its antiretroviral (ARV) drug Avonza™ (TLE400). Avonza™ is a fixed-dose combination comprised of Efavirenz, Lamivudine and Tenofovir Disoproxil Fumarate Tablets, 400 mg/300 mg/300 mg, recommended by the World Health Organization (WHO) as an alternative first-line regimen for people being treated for HIV/AIDS.
Commenting on the launch, Mylan President Rajiv Malik said, “Developing Avonza™ and bringing it to patients with HIV in India is a continuation of our strong and sustained commitment to expanding access to affordable, high quality ARVs. Avonza™ will be available to patients at a cost that is lower than that of other current first-line ARVs. What’s more, Mylan is the first to offer this combination in India, making it another example of the innovative spirit that runs throughout our company to adapt our medicines, accelerate access and improve treatment outcomes.”
In April 2017, the Health Ministry in India launched the Test and Treat Policy for HIV; anyone testing positive for HIV will get antiretroviral therapy irrespective of CD4 count or clinical stage.
Mylan’s Avonza™ also is another step the company is taking to assist India meet its Sustainable Development Aim of ending AIDS by 2030.
Globally, Mylan supplies life-saving ARVs to nearly 50% of patients being treated for HIV/AIDS in more than 100 developing countries. The company’s comprehensive ARV portfolio includes 14 active pharmaceutical ingredients and 50 finished dosage forms in first-line, second-line and pediatric formulations.
The stock closed its last trade at the price of $31.78, while exchanging hands with the volume of 11382536 shares contrast to its average daily volume of 5.43M shares. Trading volume is an important technical indicator a shareholder uses to confirm a trend or trend reversal. It is generally higher when the price of a security is changing, as the strength of any given price movement is measured mainly by the volume and shifts in trade volume can make observed price movements more significant. News about a company’s financial status, products, or plans, whether positive or negative, will typically result in a temporary increase in the trade volume of its stock. Higher volume for a stock is also an indicator of higher liquidity in the market. For institutional shareholders who wish to sell a large number of shares of a certain stock, lower liquidity will force them to sell the stock slowly over a longer period of time, to avoid losses because of slippage. The stock, as of recent close, has shown weekly downbeat performance of -17.62% which was maintained at -15.72% in 1-month period, and is down -16.67% in this year. The company now has a market value of $17.96B.
The stock, after recent close, is -16.91% below their SMA 50 and -15.94% from SMA20 and is -17.62% above than SMA200. 75.04% shares of the company were owned by institutional investors. The company has 1.55 value in price to sale ratio while price to book ratio was recorded as 1.46. It beta stands at 1.29.
The average 12 month target price among brokers that have covered the stock in the last year is $48. Analyst mean recommendation for this stock stands at 2.10. Analyst recommendations as stated on FINVIZ are rated on a 1 to 5 scale. 1 is equivalent to a buy rating, 3 a hold rating, and 5 a sell rating. The consensus recommendation is the average rating on a stock by the analyst community.
